Murdo  Gordon net worth and biography

Murdo Gordon Biography and Net Worth

EVP of Amgen

Murdo Gordon is executive vice president, Global Commercial Operations for Amgen. In this role, which he assumed in September 2018, Gordon is responsible for ensuring Amgen’s innovative medicines reach patients around the world.

Prior to joining Amgen, Gordon served in a variety of leadership positions during a nearly 30-year career at Bristol-Myers Squibb (BMS). His last role there was Chief Commercial Officer with responsibility for commercial strategy globally, including all sales and marketing activities, as well as customer operations, access and pricing. Previously, Gordon served as head of worldwide markets with responsibility for the promotion of all BMS brands globally. This was preceded by his work as president of BMS’ U.S. operations, a role he assumed in 2013.

Gordon joined BMS in 1989 and spent the first 14 years of his career in Canada, after receiving a Bachelor of Science in Cell and Molecular Biology from Concordia University, Montreal. In addition, he participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France.

What is Murdo Gordon's net worth?

The estimated net worth of Murdo Gordon is at least $12.06 million as of August 10th, 2023. Mr. Gordon owns 44,308 shares of Amgen stock worth more than $12,057,979 as of December 11th. This net worth estimate does not reflect any other assets that Mr. Gordon may own. Additionally, Mr. Gordon receives a salary of $2,720,000.00 as EVP at Amgen. Learn More about Murdo Gordon's net worth.

How old is Murdo Gordon?

Mr. Gordon is currently 56 years old. There are 7 older executives and no younger executives at Amgen. The oldest executive at Amgen is Mr. Peter H. Griffith, Executive VP & CFO, who is 64 years old. Learn More on Murdo Gordon's age.

What is Murdo Gordon's salary?

As the EVP of Amgen Inc., Mr. Gordon earns $2,720,000.00 per year. There are 2 executives that earn more than Mr. Gordon. The highest earning executive at Amgen is Mr. Robert A. Bradway, Chairman, CEO & President, who commands a salary of $5,490,000.00 per year. Learn More on Murdo Gordon's salary.

How do I contact Murdo Gordon?

The corporate mailing address for Mr. Gordon and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Murdo Gordon's contact information.

Has Murdo Gordon been buying or selling shares of Amgen?

Murdo Gordon has not been actively trading shares of Amgen during the last quarter. Most recently, Murdo Gordon sold 9,558 shares of the business's stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $262.43, for a transaction totalling $2,508,305.94. Following the completion of the sale, the executive vice president now directly owns 44,308 shares of the company's stock, valued at $11,627,748.44. Learn More on Murdo Gordon's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & CEO), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, Amgen insiders bought shares 1 times. They purchased a total of 1,764,705 shares worth more than $29,999,985.00. During the last year, insiders at the medical research company sold shares 3 times. They sold a total of 21,654 shares worth more than $5,808,676.82. The most recent insider tranaction occured on December, 4th when SVP Nancy A Grygiel sold 2,096 shares worth more than $572,270.88. Insiders at Amgen own 0.5% of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 12/4/2023.

Murdo Gordon Insider Trading History at Amgen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/10/2023Sell9,558$262.43$2,508,305.9444,308View SEC Filing Icon  
See Full Table

Murdo Gordon Buying and Selling Activity at Amgen

This chart shows Murdo Gordon's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $272.14
Low: $270.42
High: $275.90

50 Day Range

MA: $270.22
Low: $255.70
High: $286.88

2 Week Range

Now: $272.14
Low: $211.71
High: $288.46


2,779,210 shs

Average Volume

2,452,672 shs

Market Capitalization

$145.64 billion

P/E Ratio


Dividend Yield